4
Changes in Ownership
BIOCRYST PHARMACEUTICALS INC Filed Acc 0001127602-19-018347
Senior Vice President and CFO sold 19,500 shares at an average $7.70 ($150,053)
- Senior Vice President and CFO acquired 19,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-09 | Option exercise | +9,750 | $5.51 | $53,723 | 142,426 | D: show line 1 in the form |
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-09 | Sale | −9,750 | $7.63 | $74,393 | 132,676 | D: show line 2 in the form |
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-13 | Option exercise | +9,750 | $5.51 | $53,723 | 142,426 | D: show line 3 in the form |
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-13 | Sale | −9,750 | $7.76 | $75,660 | 132,676 | D: show line 4 in the form |
| Open-market sales · 19,500 sh · avg $7.70 · $150,053 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-09 | Option exercise · Emp. Stock Option (Right to Buy) | −9,750 | 141,000 | D: show line 5 in the form | |||||
| STAAB THOMAS R II Senior Vice President and CFO | 2019-05-13 | Option exercise · Emp. Stock Option (Right to Buy) | −9,750 | 131,250 | D: show line 6 in the form |
Loading xslF345X03/form4.xml…